---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-24-005445"
form_type: "8-K"
ticker: "AEMD"
cik: "0000882291"
company_name: "AETHLON MEDICAL INC"
filed_at: "2024-08-12T23:59:59+00:00"
generated_at: "2026-05-31T10:15:12.566529+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aethlon Medical receives second ethics approval for Hemopurifier cancer trial in Australia

## Summary
- Bellberry Human Research Ethics Committee granted full ethics approval to Pindara Private Hospital for Hemopurifier trial in solid tumors not responding to anti-PD-1 antibodies.
- This is the second ethics committee approval; the first came from Royal Adelaide Hospital in June 2024.
- The trial will be conducted by Dr. Marco Matos at Pindara Private Hospital in Queensland, Australia.
- Next steps include Research Governance Office approval, then Site Initiation Visits before patient enrollment can begin.
- Primary endpoint is safety; the trial plans to enroll 9–18 patients and will explore extracellular vesicle reduction.

## SEC filing metadata
- accession: 0001683168-24-005445
- form_type: 8-K
- ticker: AEMD
- cik: 0000882291
- company_name: AETHLON MEDICAL INC
- filed_at: 2024-08-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882291/000168316824005445/0001683168-24-005445-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882291/000168316824005445/aethlon_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-24-005445
- JSON: https://secwatch.observer/filing/0001683168-24-005445.json
- Plain text: https://secwatch.observer/filing/0001683168-24-005445.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.